Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Oliver Sartor

Showing results (1-10 of 508) with videos related to

Pageof 51
Sort By:
Nature Reviews. Urology|September 7, 2010
Prostate cancer. Saturation biopsy does not accurately localize tumorsOliver Sartor
JNCI Cancer Spectrum|November 12, 2023
Radium-223 and bone metastatic disease: still more to learnOliver Sartor
Clinical Genitourinary Cancer|July 25, 2007
Chemotherapy in prostate cancer: an updateOliver Sartor
Clinical Prostate Cancer|October 14, 2004
Prostate cancer and bone: a unique relationship with multiple opportunities for targeted therapyOliver Sartor
Clinical Genitourinary Cancer|May 30, 2006
The continuing challenge of hormone-refractory prostate cancerOliver Sartor
The Lancet. Oncology|October 19, 2022
Predicting benefit from [<sup>177</sup>Lu]Lu-PSMA-617 therapy: what do we need to know?Oliver Sartor
Nature Reviews. Urology|November 1, 2016
Prostate cancer: What is the optimal treatment sequence for mCRPC?Oliver Sartor
The Oncologist|October 26, 2018
Conflicts of Interest, Baselga, and Clinical TrialistsOliver Sartor
BJU International|November 1, 2012
Diethylstilbestrol in castration-resistant prostate cancerOliver Sartor
Clinical Advances in Hematology & Oncology : H&O|June 4, 2014
Radium-223: the newest option in metastatic castration-resistant prostate cancerOliver Sartor
Pageof 51

Showing results (1-10 of 508) with videos related to

Sort By:
Pageof 51
Nature Reviews. Urology|September 7, 2010
Prostate cancer. Saturation biopsy does not accurately localize tumorsOliver Sartor
JNCI Cancer Spectrum|November 12, 2023
Radium-223 and bone metastatic disease: still more to learnOliver Sartor
Clinical Genitourinary Cancer|July 25, 2007
Chemotherapy in prostate cancer: an updateOliver Sartor
Clinical Prostate Cancer|October 14, 2004
Prostate cancer and bone: a unique relationship with multiple opportunities for targeted therapyOliver Sartor
Clinical Genitourinary Cancer|May 30, 2006
The continuing challenge of hormone-refractory prostate cancerOliver Sartor
The Lancet. Oncology|October 19, 2022
Predicting benefit from [<sup>177</sup>Lu]Lu-PSMA-617 therapy: what do we need to know?Oliver Sartor
Nature Reviews. Urology|November 1, 2016
Prostate cancer: What is the optimal treatment sequence for mCRPC?Oliver Sartor
The Oncologist|October 26, 2018
Conflicts of Interest, Baselga, and Clinical TrialistsOliver Sartor
BJU International|November 1, 2012
Diethylstilbestrol in castration-resistant prostate cancerOliver Sartor
Clinical Advances in Hematology & Oncology : H&O|June 4, 2014
Radium-223: the newest option in metastatic castration-resistant prostate cancerOliver Sartor
Pageof 51